|
US2014142038A1
|
|
Method of treating coronary artery disease by administering FGF-9
|
|
AU2013206610A1
|
|
Analysis of saccharide vaccines without interference
|
|
AU2013206190A1
|
|
Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
|
|
AU2012261538A1
|
|
Reducing interference between oil-containing adjuvants and surfactant-containing antigens
|
|
AU2012241070A1
|
|
Immunogens from uropathogenic Escherichia Coli
|
|
AU2012211495A1
|
|
Immunogenic bacterial vesicles with outer membrane proteins
|
|
JP2012107074A
|
|
Small molecule immunopotentiator and assay for the detection
|
|
EP2331120A1
|
|
Factor h binding protein immunogens
|
|
CA2705787A1
|
|
Methods of generating alphavirus particles
|
|
WO2009029569A1
|
|
Hiv env proteins with modifications in the v3 loop
|
|
GB0810894D0
|
|
Conjugated saccharide
|
|
ZA200802168B
|
|
Antagonist anti-CD40 monoclonal antibodies and methods for their use
|
|
AU2007231768A1
|
|
Immunisation against Chlamydia trachomatis
|
|
US2010166788A1
|
|
Immunogens from uropathogenic escherichia coli
|
|
EP2046808A2
|
|
Methods and reagents for detecting hantavirus
|
|
WO2007124382A2
|
|
Inhaled imipenem
|
|
US2008045528A1
|
|
6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
|
|
TW200808739A
|
|
Quinazolines for PDK1 inhibition
|
|
WO2007110776A1
|
|
Storage of influenza vaccines without refrigeration
|
|
GB0700562D0
|
|
Modified Saccharides
|
